Lifetime Attributable Risk for Breast Cancer Induced by High-Resolution Computed Tomography During COVID-19 Pandemic.

Journal of Family and Reproductive Health Pub Date : 2024-12-01 DOI:10.18502/jfrh.v18i4.17429

Roya Sahebi, Jafar Hassanzadeh, Rezvan Ravanfar Haghighi, Mehrzad Lotfi, Alireza Mirahmadizadeh

{"title":"Lifetime Attributable Risk for Breast Cancer Induced by High-Resolution Computed Tomography During COVID-19 Pandemic.","authors":"Roya Sahebi, Jafar Hassanzadeh, Rezvan Ravanfar Haghighi, Mehrzad Lotfi, Alireza Mirahmadizadeh","doi":"10.18502/jfrh.v18i4.17429","DOIUrl":null,"url":null,"abstract":"Objective: The widespread utilization of high-resolution computed tomography (HRCT) for diagnosing and management of COVID-19 during the pandemic has prompted worries regarding a potential rise in future breast cancer cases. We aimed to estimate the Life Attributable Risk (LAR) of breast cancer in Shiraz, Iran, linked to HRCT use during the COVID-19 pandemic.Materials and methods: A cross-sectional study was conducted at Namazi Hospital in Shiraz from February 2, 2020, to December 31, 2022.The Imaging Performance Assessment of CT Scanners (ImPACT) patient dosimetry calculator was used to determine organ doses. LAR was computed utilizing the Biological Effects of Ionizing Radiation (BEIR) Committee models.Results: The sample size was 666, with ages spanning from 15 to 95 years. 25% (168) had HRCT more than once (2 to 8 times). The mean and 95% uncertainty limits (UL) for Total LAR of breast cancer, considering both single and multiple doses of radiation exposure, was 217 (95% UL, 194-244) per 100,000 persons.Conclusion: According to our research, the risk of potential breast cancer should not be overlooked. It is advised to use the ultra-low-dose protocol over the low-dose in HRCT. Physicians, pulmonologists, and infectious disease specialists are advised to avoid unnecessary and repeated requests for chest HRCT in a short period.","PeriodicalId":15845,"journal":{"name":"Journal of Family and Reproductive Health","volume":"18 4","pages":"274-280"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12056439/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Family and Reproductive Health","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18502/jfrh.v18i4.17429","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: The widespread utilization of high-resolution computed tomography (HRCT) for diagnosing and management of COVID-19 during the pandemic has prompted worries regarding a potential rise in future breast cancer cases. We aimed to estimate the Life Attributable Risk (LAR) of breast cancer in Shiraz, Iran, linked to HRCT use during the COVID-19 pandemic.

Materials and methods: A cross-sectional study was conducted at Namazi Hospital in Shiraz from February 2, 2020, to December 31, 2022.The Imaging Performance Assessment of CT Scanners (ImPACT) patient dosimetry calculator was used to determine organ doses. LAR was computed utilizing the Biological Effects of Ionizing Radiation (BEIR) Committee models.

Results: The sample size was 666, with ages spanning from 15 to 95 years. 25% (168) had HRCT more than once (2 to 8 times). The mean and 95% uncertainty limits (UL) for Total LAR of breast cancer, considering both single and multiple doses of radiation exposure, was 217 (95% UL, 194-244) per 100,000 persons.

Conclusion: According to our research, the risk of potential breast cancer should not be overlooked. It is advised to use the ultra-low-dose protocol over the low-dose in HRCT. Physicians, pulmonologists, and infectious disease specialists are advised to avoid unnecessary and repeated requests for chest HRCT in a short period.

查看原文本刊更多论文

2019冠状病毒病大流行期间高分辨率计算机断层扫描诱发乳腺癌的终生归因风险

目的：高分辨率计算机断层扫描（HRCT）在COVID-19大流行期间广泛应用于诊断和管理，引发了人们对未来乳腺癌病例可能上升的担忧。我们的目的是估计伊朗设拉子地区乳腺癌的生命归因风险（LAR），该风险与COVID-19大流行期间HRCT的使用有关。材料和方法：横断面研究于2020年2月2日至2022年12月31日在设拉子Namazi医院进行。使用CT扫描仪成像性能评估（ImPACT）患者剂量计算器确定器官剂量。LAR是利用电离辐射生物效应（BEIR）委员会模型计算的。结果：样本量为666例，年龄在15 ~ 95岁之间。25%（168例）HRCT检查超过1次（2 ~ 8次）。考虑到单次和多次辐射暴露，乳腺癌总LAR的平均和95%不确定限（UL）为每10万人217例（95% UL， 194-244例）。结论：根据我们的研究，乳腺癌的潜在风险不容忽视。建议在HRCT中使用超低剂量方案而不是低剂量方案。建议内科医生、肺科医生和传染病专家在短时间内避免不必要和重复的胸部HRCT检查要求。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Family and Reproductive Health

自引率

0.00%

发文量

审稿时长

5 weeks

期刊介绍： The Journal of Family & Reproductive Health (JFRH) is the quarterly official journal of Vali–e–Asr Reproductive Health Research Center. This journal features fulllength, peerreviewed papers reporting original research, clinical case histories, review articles, as well as opinions and debates on topical issues. Papers published cover the scientific and medical aspects of reproductive physiology and pathology including genetics, endocrinology, andrology, embryology, gynecologic urology, fetomaternal medicine, oncology, infectious disease, public health, nutrition, surgery, menopause, family planning, infertility, psychiatry–psychology, demographic modeling, perinatalogy–neonatolgy ethics and social issues, and pharmacotherapy. A high scientific and editorial standard is maintained throughout the journal along with a regular rate of publication. All published articles will become the property of the JFRH. The editor and publisher accept no responsibility for the statements expressed by the authors here in. Also they do not guarantee, warrant or endorse any product or service advertised in the journal.